Ads
related to: alnylam pharmaceuticals cambridge ma careers- Latest Jobs in Chicago
Right role for the right Candidate
Explore millions of Vacancies
- Jobs in North Carolina
245 Vacancies available
in your City. Don't miss any.
- Jobs in California
Explore the lastes jobs
in your City
- Latest Jobs in Dallas, Tx
763 Vacancies available
in your City. Apply now!
- Latest Jobs in Chicago
Employment.org has been visited by 100K+ users in the past month
Large Employment Site (>10 Million Unique Visitors Per Month) - TAtech
Search results
Results from the WOW.Com Content Network
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. [4]
As of 2016 Alnylam remained the dominant company in the RNAi field. [ 12 ] [ 13 ] Alnylam has achieved approval for 5 medicines. In 2003 he co-founded Acceleron Pharma as CEO with scientists Jasbir Seehra, Tom Maniatis , Mark Ptashne , Wylie Vale , and scientific advisor Joan Massague , and John Knopf.
The fifth RNAi therapeutic medicine, AMVUTTRA, was approved in 2021. At Alnylam, he forged over 25 major partnerships with leading pharmaceutical and biotechnology companies, raised over $7.5 billion to fund the company’s research, development, manufacturing, and commercialization activities, and built $25 billion in market capitalization value.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today its key "Alnylam 5x15™" pipeline and partner program goals ...
PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Medicines Company (NAS: MDCO) and Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that ...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...
Greenstreet became Alnylam's chief operating officer in 2016. In 2021, it was announced that John Maraganore would step down as Alnylam's CEO on 1 January 2022, and would be succeeded by Greenstreet. [1]
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi ...